Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 8506370, 8 pages
https://doi.org/10.1155/2017/8506370
Clinical Study

Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study

1Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
3Department of Cardiology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
4Department of Radiology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
5Department of Cardiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
6Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
7Department of Radiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
8Department of Radiology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
9Department of Radiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

Correspondence should be addressed to Jens Kastrup; kd.hnoiger@purtsak.snej

Received 31 May 2017; Accepted 24 August 2017; Published 19 September 2017

Academic Editor: Bojan Vrtovec

Copyright © 2017 Jens Kastrup et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Andrew, G. C. Fonarow, J. Butler et al., “The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries,” Journal of the American College of Cardiology, vol. 63, no. 12, pp. 1123–1133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Kastrup, N. D. Mygind, A. A. Qayyum, A. B. Mathiasen, M. Haack-Sørensen, and A. Ekblond, “Mesenchymal stromal cell therapy in ischemic heart disease,” Scandinavian Cardiovascular Journal, vol. 50, no. 5-6, pp. 293–299, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Fisher, C. Doree, S. J. Brunskill, A. Mathur, and E. Martin-Rendon, “Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis,” PLoS One, vol. 8, article e64669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Hass, C. Kasper, S. Böhm, and R. Jacobs, “Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC,” Cell Communication and Signaling: CCS, vol. 9, 12 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Gyongyosi, W. Wojakowski, P. Lemarchand et al., “Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocaridal infarction based on individual patient data,” Circulation Research, vol. 116, no. 8, pp. 1346–1360, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Juhl, J. Tratwal, B. Follin et al., “Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 76, no. 2, pp. 93–104, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Friis, M. Haack-Sørensen, A. B. Mathiasen et al., “Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina,” Scandinavian Cardiovascular Journal, vol. 45, no. 3, pp. 161–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Haack-Sørensen, T. Friis, A. B. Mathiasen et al., “Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up,” Cell Transplantation, vol. 22, no. 3, pp. 521–528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. B. Mathiasen, M. Haack-Sørensen, E. Jørgensen, and J. Kastrup, “Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina-final 3-year follow-up,” International Journal of Cardiology, vol. 170, no. 2, pp. 246–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. B. Mathiasen, A. A. Qayyum, E. Jørgensen et al., “Bone-marrow derived mesenchymal stromal cell treatment in patients with severe ischemic heart failure: a randomised placebo-controlled trial (MSC-HF trial),” European Heart Journal, vol. 36, no. 27, pp. 1744–1753, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. A. Qayyum, M. Haack-Sørensen, A. B. Mathiasen, E. Jørgensen, A. Ekblond, and J. Kastrup, “Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design,” Regenerative Medicine, vol. 7, no. 3, pp. 421–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Kastrup, M. Haack-Sørensen, M. Juhl et al., “Cryopreserved off-the-shelf allogeneic adipose-derived stromal cells for therapy in patients with ischemic heart disease and heart failure – a safety study,” Stem Cell Translational Medicine, 2017, In press. View at Publisher · View at Google Scholar
  13. M. Haack-Sørensen, B. Follin, M. Juhl et al., “Culture expansion of adipose derived stromal cells. A closed automated quantum cell expansion system compared with manual flask-based culture,” Journal of Translational Medicine, vol. 14, no. 1, 319 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Follin, J. Tratwal, M. Haack-Sørensen, J. J. Elberg, J. Kastrup, and A. Ekblond, “Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease,” Journal of Translational Medicine, vol. 11, no. 1, 219 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. H. D. White, R. M. Norris, M. A. Brown, P. W. Brandt, R. M. Whitlock, and C. J. Wild, “Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction,” Circulation, vol. 76, pp. 44–51, 1987. View at Publisher · View at Google Scholar
  16. B. A. Groenning, J. C. Nilsson, L. Sondergaard, T. Fritz-Hansen, B. W. Larsson, and P. R. Hildebrandt, “Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure,” Journal of the American College of Cardiology, vol. 36, pp. 2072–2080, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, pp. 2277–2286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. L. Chen, W. W. Fang, F. Ye et al., “Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction,” The American Journal of Cardiology, vol. 94, no. 1, pp. 92–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. D. G. Katritsis, P. Sotiropoulou, E. Giazitzoglou, E. Karvouni, and M. Papamichail, “Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells,” Europace, vol. 9, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Yang, F. Zhang, W. Ma et al., “A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery,” Cardiovascular Therapeutics, vol. 28, pp. 380–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Houtgraaf, W. K. den Dekker, B. M. van Dalen et al., “First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction,” Journal of the American College of Cardiology, vol. 59, pp. 539-540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,” The Journal of the American Medical Association, vol. 308, pp. 2369–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. E. C. Perin, K. M. Borow, G. V. Silva et al., “A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure,” Circulation Research, vol. 117, pp. 576–584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Hare, D. F. DL, A. C. Rieger et al., “Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial,” Journal of the American College of Cardiology, vol. 69, no. 5, pp. 526–537, 2017. View at Publisher · View at Google Scholar
  25. S. Chen, Z. Liu, N. Tian et al., “Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery,” The Journal of Invasive Cardiology, vol. 18, pp. 552–556, 2006. View at Google Scholar
  26. M. Mohyeddin-Bonab, M. R. Mohamad-Hassani, K. Alimoghaddam et al., “Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction,” Archives of Iranian Medicine, vol. 10, pp. 467–473, 2007. View at Google Scholar
  27. A. R. Williams, B. Trachtenberg, D. L. Velazquez et al., “Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling,” Circulation Research, vol. 108, pp. 792–796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. G. P. Lasala, J. A. Silva, B. A. Kusnick, and J. J. Minguell, “Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study,” Cardiovascular Revascularization Medicine, vol. 12, no. 1, pp. 29–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Strioga, S. Viswanathan, A. Darinskas, O. Slaby, and J. Michalek, “Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells,” Stem Cells and Development, vol. 21, pp. 2724–2751, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Torensma, H. J. Prins, E. Schrama et al., “The impact of cell source, culture methodology, culture location, and individual donors on gene expression profiles of bone marrow-derived and adipose-derived stromal cells,” Stem Cells and Development, vol. 22, pp. 1086–1095, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Heo, Y. Choi, H.-S. Kim, and H. O. Kim, “Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue,” International Journal of Molecular Medicine, vol. 37, pp. 115–125, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Naftali-Shani, A. Itzhaki-Alfia, N. Landa-Rouben et al., “The origin of human mesenchymal stromal cells dictates their reparative properties,” Journal of the American Heart Association, vol. 2, no. 5, article e000253, 2013. View at Publisher · View at Google Scholar
  33. A. Gebler, O. Zabel, and B. Seliger, “The immunomodulatory capacity of mesenchymal stem cells,” Trends in Molecular Medicine, vol. 18, pp. 128–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. G. M. Spaggiari, A. Gapobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2,” Blood, vol. 111, pp. 1327–1333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Melief, J. J. Zwaginga, W. E. Fibbe, and H. Roelofs, “Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts,” Stem Cells Translational Medicine, vol. 2, pp. 455–463, 2013. View at Publisher · View at Google Scholar · View at Scopus